Last Patient / Last Visit Completed Topline Data Readout Expected Later This Quarter CRANBURY, N.J., Feb. 6, 2025 /PRNewswire/ -- Palatin Technologies, Inc.

Inc. (NYSE American: PTN) has announced the completion of their Phase 2 clinical trial for an obesity treatment, marking a ...

Palatin Technologies, Inc. , a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the ...

Online pharmacies will now have to employ stricter checks to stop people who are already a healthy weight or have a history ...

Wall Street is bullish on Viking, but the company still has a lot to prove. Viking has a number of different clinical studies ...

Two months after launching Pep2Tango Therapeutics, VC firm Versant Ventures is unveiling another obesity-focused biotech in ...

An experimental drug called amycretin showed signs it could be more potent than Eli Lilly’s rival Zepbound, though analysts ...

Lexaria Bioscience Corp., a global innovator in drug delivery platforms, announced that it has received the necessary independent ethics board approval required for its contract research organization ...

A massive John Deere excavator owned by Green Infrastructure Partners Inc. (GIP) rumbled on to the old General Hospital site ...

Pantginis emphasizes that VK2735, a dual GLP-1/GIP receptor agonist, may demonstrate superior weight loss outcomes compared to semaglutide, which only targets GLP-1. Notably, the Phase 2 VENTURE ...

Tirzepatide, a dual agonist of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, represents a novel therapeutic option for both glycemic control and ...

今日（1月14日），恒瑞医药宣布，其与美国Kailera Therapeutics公司共同正在共同开发的GLP-1/GIP双受体激动剂HRS9531注射液8mg在减重2 ...